167 related articles for article (PubMed ID: 20579864)
1. Serum adipocyte-specific fatty acid-binding protein is associated with nonalcoholic fatty liver disease in apparently healthy subjects.
Kim YC; Cho YK; Lee WY; Kim HJ; Park JH; Park DI; Sohn CI; Jeon WK; Kim BI; Park SE; Rhee EJ; Park CY; Oh KW; Park SW; Kim SW; Ryu SH
J Nutr Biochem; 2011 Mar; 22(3):289-92. PubMed ID: 20579864
[TBL] [Abstract][Full Text] [Related]
2. Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients.
Koh JH; Shin YG; Nam SM; Lee MY; Chung CH; Shin JY
Diabetes Care; 2009 Jan; 32(1):147-52. PubMed ID: 18835952
[TBL] [Abstract][Full Text] [Related]
3. Serum adipocyte fatty acid-binding protein levels: An indicator of non-alcoholic fatty liver disease in Chinese individuals.
Xu Y; Ma X; Pan X; He X; Wang Y; Bao Y
Liver Int; 2019 Mar; 39(3):568-574. PubMed ID: 30554468
[TBL] [Abstract][Full Text] [Related]
4. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study.
Xu A; Tso AW; Cheung BM; Wang Y; Wat NM; Fong CH; Yeung DC; Janus ED; Sham PC; Lam KS
Circulation; 2007 Mar; 115(12):1537-43. PubMed ID: 17389279
[TBL] [Abstract][Full Text] [Related]
5. Serum AFBP levels are elevated in patients with nonalcoholic fatty liver disease.
Suh JB; Kim SM; Cho GJ; Choi KM
Scand J Gastroenterol; 2014 Aug; 49(8):979-85. PubMed ID: 24957697
[TBL] [Abstract][Full Text] [Related]
6. Increased H-FABP concentrations in nonalcoholic fatty liver disease. Possible marker for subclinical myocardial damage and subclinical atherosclerosis.
Başar O; Akbal E; Köklü S; Tuna Y; Koçak E; Başar N; Tok D; Erbiş H; Senes M
Herz; 2013 Jun; 38(4):417-22. PubMed ID: 23324907
[TBL] [Abstract][Full Text] [Related]
7. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome.
Xu A; Wang Y; Xu JY; Stejskal D; Tam S; Zhang J; Wat NM; Wong WK; Lam KS
Clin Chem; 2006 Mar; 52(3):405-13. PubMed ID: 16423904
[TBL] [Abstract][Full Text] [Related]
8. Fetuin-B links nonalcoholic fatty liver disease to type 2 diabetes via inducing insulin resistance: Association and path analyses.
Li Z; Lin M; Liu C; Wang D; Shi X; Chen Z; Liu Y; Yang S; Li X
Cytokine; 2018 Aug; 108():145-150. PubMed ID: 29609136
[TBL] [Abstract][Full Text] [Related]
9. The influence of waist circumference on insulin resistance and nonalcoholic fatty liver disease in apparently healthy Korean adults.
Ju DY; Choe YG; Cho YK; Shin DS; Yoo SH; Yim SH; Lee JY; Park JH; Kim HJ; Park DI; Sohn CI; Jeon WK; Kim BI
Clin Mol Hepatol; 2013 Jun; 19(2):140-7. PubMed ID: 23837138
[TBL] [Abstract][Full Text] [Related]
10. Association of serum adipocyte-specific Fatty Acid binding protein with Fatty liver index as a predictive indicator of nonalcoholic Fatty liver disease.
Jeon WS; Park SE; Rhee EJ; Park CY; Oh KW; Park SW; Lee WY
Endocrinol Metab (Seoul); 2013 Dec; 28(4):283-7. PubMed ID: 24396693
[TBL] [Abstract][Full Text] [Related]
11. Serum adipocyte fatty acid-binding protein levels are associated with peripheral arterial disease in women, but not men, with type 2 diabetes mellitus.
Ding M; Shi JY; Xing YZ; Sun B; Fang QH; Zhang JY; Zhang QM; Chen LM; Yu DM; Li CJ
J Diabetes; 2018 Jun; 10(6):478-486. PubMed ID: 28303680
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians.
Thakur ML; Sharma S; Kumar A; Bhatt SP; Luthra K; Guleria R; Pandey RM; Vikram NK
Atherosclerosis; 2012 Aug; 223(2):507-11. PubMed ID: 22748277
[TBL] [Abstract][Full Text] [Related]
13. Serum osteocalcin is inversely associated with adipocyte-specific fatty acid-binding protein in the Korean metabolic syndrome research initiatives.
Lee YJ; Lee H; Jee SH; Lee SS; Kim SR; Kim SM; Lee MW; Lee CB; Oh S
Diabetes Care; 2010 Jul; 33(7):e90. PubMed ID: 20587710
[No Abstract] [Full Text] [Related]
14. Anthropometric measures of visceral and subcutaneous fat are important in the determination of metabolic dysregulation in boys and girls at risk for nonalcoholic fatty liver disease.
Mager DR; Yap J; Rodriguez-Dimitrescu C; Mazurak V; Ball G; Gilmour S
Nutr Clin Pract; 2013 Feb; 28(1):101-11. PubMed ID: 23042833
[TBL] [Abstract][Full Text] [Related]
15. Association of hepatic insulin resistance indexes to nonalcoholic fatty liver disease and related biomarkers.
Sesti G; Fiorentino TV; Hribal ML; Sciacqua A; Perticone F
Nutr Metab Cardiovasc Dis; 2013 Dec; 23(12):1182-7. PubMed ID: 23419734
[TBL] [Abstract][Full Text] [Related]
16. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men.
Park SH; Kim BI; Yun JW; Kim JW; Park DI; Cho YK; Sung IK; Park CY; Sohn CI; Jeon WK; Kim H; Rhee EJ; Lee WY; Kim SW
J Gastroenterol Hepatol; 2004 Jun; 19(6):694-8. PubMed ID: 15151626
[TBL] [Abstract][Full Text] [Related]
17. [Insulin-like growth factor-binding protein-1: a new biochemical marker of nonalcoholic fatty liver disease?].
Graffigna MN; Belli SH; de Larrañaga G; Fainboim H; Estepo C; Peres S; García N; Levalle O
Acta Gastroenterol Latinoam; 2009 Mar; 39(1):30-7. PubMed ID: 19408737
[TBL] [Abstract][Full Text] [Related]
18. Role of APN and TNF-α in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease.
Lin X; Zhang Z; Chen JM; Xu YY; Ye HR; Cui J; Fang Y; Jin Y; Zhu DR; Yuan L
Genet Mol Res; 2015 Apr; 14(2):2940-6. PubMed ID: 25966055
[TBL] [Abstract][Full Text] [Related]
19. Insulin Resistance but Not Visceral Adiposity Index Is Associated with Liver Fibrosis in Nondiabetic Subjects with Nonalcoholic Fatty Liver Disease.
Ercin CN; Dogru T; Genc H; Celebi G; Aslan F; Gurel H; Kara M; Sertoglu E; Tapan S; Bagci S; Rizzo M; Sonmez A
Metab Syndr Relat Disord; 2015 Sep; 13(7):319-25. PubMed ID: 26011302
[TBL] [Abstract][Full Text] [Related]
20. Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment.
Haluzík MM; Anderlová K; Doležalová R; Adamíková A; Haluzíková D; Housová J; Svacina S; Haluzík M
Physiol Res; 2009; 58(1):93-99. PubMed ID: 18198986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
